Live Chat

交易 BioNTech BNTX

BioNTech實時圖表

金融工具基礎知識

Weekly Search
Weekly
Daily
日期  關閉 更改 更改(%): 開倉

聯絡方式

點差

0.7902

點差(%)

0.7099 %

槓桿

1:10

隔夜利息(買入)

-0.0597 %

隔夜利息(賣出)

-0.0292 %

貨幣

USD

交易時間

市場關閉

星期一

13:31 - 19:59

星期二

13:31-19:59

星期三

13:31-19:59

星期四

13:31-19:59

星期五

13:31-19:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

25565874176

流通股份

239740000

收益日期(下一個)

0000-00-00

現金殖利率 

2022-06-17

除息日

2022-06-02

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-2.03

了解有關此金融工具的詳細資訊

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

相關工具

資產
出售
購買
更改(%):
查看所有金融工具

最新新聞

隨時了解全球各地的最新金融資訊。

星期四, 7 十一月 2024

11月7日財經:特朗普勝選美股大盤指數全綫大漲,比特幣價格再創新高

星期三, 6 十一月 2024

11月6日財經:美國總統大選市場波動,比特幣價格創下歷史新高

星期二, 5 十一月 2024

黃金價格走勢受避險需求與美國降息預期支撐,突破或回調成焦點

星期一, 4 十一月 2024

11月4日財經速讀:美国大选前夕股市保持谨慎

星期二, 29 十月 2024

10/30 財經速讀:科技股財報利好刺激納斯達克創新高

星期二, 29 十月 2024

10月29日財經:油價回落,比特幣突破70000美元

星期一, 28 十月 2024

10月28日財經:納斯達克創新高,本周科技巨頭財報成焦點

星期五, 25 十月 2024

10月25日財經:美股指數表現分化,特斯拉帶動科技股反彈

Trustpilot
Live Chat